Free press releases distribution network?

Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Donald Huddler, GSK to Present on Fragment Screening At Assay Meeting, October 24-26 in Philadelphia - Donald Huddler, Investigator of Biophysics Group – Computational and Structural Chemistry at GlaxoSmithKline will give a presentation at GTC’s 7th Assay & Drug Discovery Technologies conference (October 24th-26th, 2012 in Philadelphia, PA) - GTCbio.com
Donald Huddler, GSK to Present on Fragment Screening At Assay Meeting, October 24-26 in Philadelphia

 

PRZOOM - /newswire/ - Monrovia, CA, United States, 2012/09/20 - Donald Huddler, Investigator of Biophysics Group – Computational and Structural Chemistry at GlaxoSmithKline will give a presentation at GTC’s 7th Assay & Drug Discovery Technologies conference (October 24th-26th, 2012 in Philadelphia, PA) - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Donald Huddler, Investigator of Biophysics Group – Computational and Structural Chemistry at GlaxoSmithKline will give a presentation on ‘Fragment Screening Strategies for Difficult or Unprecedented Targets - Leveraging SPR and NMR’ at GTC’s 7th Assay & Drug Discovery Technologies conference (October 24th-26th, 2012 in Philadelphia, PA)

An increasing percentage of the contemporary drug discovery targets are novel or with limited precedence. The majority of these novel targets have little or no chemical matter in the literature. For the small percentage of truly novel targets that do have published chemical matter, many, upon careful examination, are revealed to be nuisance mechanism compounds of no utility. Consequently, the biophysics team is left with a challenging, novel target, with no validated compounds to develop and optimize direct binding screening assays. In Dr. Huddler’s group, they have employed a general approach relying on saturation transfer difference (STD) NMR and SPR as well as a small, highly soluble, fragment library to quickly identify and validate reversibly binding compounds. Systematic application of this biophysics approach has yielded novel fragments for an array of non-traditional discovery targets.

Donald Huddler, Ph.D., is an Investigator and biophysics team leader at GlaxoSmithKline, plc in the Computational and Structural Chemistry Department (Collegeville, PA, USA). His group integrates SPR, NMR, and other biophysical methods to support Fragment-Based Lead Discovery efforts. Prior to GSK, Donald was a group leader at the Walter Reed Army Institute of Research, focused on applying structure-based drug design methods to neglected diseases and diseases common in the Developing World.

This 7th Assay & Drug Discovery Technologies Conference is part of a larger summit. Other tracks for this summit include:
• 8th Modern Drug Discovery & Development Summit
(Day 1, Oct 24, 2012) – Plenary Keynote Session
(Day 2-3, Oct 25-26, 2012) – Breakout Tracks:
• 9th Stem Cell Research & Therapeutics
• 3rd Pharmacokinetics & Pharmacodynamics
• 4th Translational Medicine Biotechnology Transfer & Commercialization.

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Donald Huddler, GSK to Present on Fragment Screening At Assay Meeting, October 24-26 in Philadelphia

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.

Visit  RightITnow Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today